17 results about "HDL cholesterol ester" patented technology

The invention relates to the technical field of biotechnology and medical detection, in particular to an ovarian cancer early-stage accurate screening method based on triple lipid metabolite chemical crosslinking, which comprises the following steps: sample collection: collecting a serum sample of a person to be detected; lipid metabolite extraction: extracting lipid metabolite from the serum sample; detection of triple lipid metabolites: simultaneously detecting the contents of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) in the lipid metabolites by adopting a liquid chromatography-mass spectrometry technology, and by simultaneously detecting the three lipid metabolites of sphingomyelin (SM), phosphatidylcholine (PC) and cholesteryl ester (CE) and carrying out chemical cross-linking analysis, the content of the triple lipid metabolites in the lipid metabolites can be detected; and calculating the triple lipid metabolite index (TLMI), so that the abnormal lipid metabolism condition of the ovarian cancer patient can be more comprehensively and accurately reflected, and the sensitivity and the specificity of early screening of the ovarian cancer are improved.

The invention relates to the technical field of specific therapeutic activity of pharmaceutical preparations, in particular to application of Avasimibe in preparation of drugs for treating pulmonary fibrosis. The invention relates to an application of Avasimibe in preparation of a medicine for treating pulmonary fibrosis. The Avasimibe is used for reducing the generation of foam cells by targeting SOAT1 so as to relieve the occurrence and development of pulmonary fibrosis. The invention reveals that Avasimibe can reduce the generation of foam cells by targeting SOAT1 so as to relieve the occurrence and development of pulmonary fibrosis. Meanwhile, it is also elaborated that Avasimibe can restore the steady state of cholesterol and cholesteryl ester, improve the fluidity of a cell membrane structure and restore the lipophagy function, and the invention develops the application of Avasimibe in treatment of pulmonary fibrosis diseases.

The present invention is directed to a cargo-loaded cholesteryl ester nanoparticle with a hollow compartment (“cholestosome”) consisting essentially of at least one non-ionic cholesteryl ester and one or more encapsulated active molecules which cannot appreciably pass through an enterocyte membrane in the absence of said molecule being loaded into said cholestosome, the cholestosome having a neutral surface and having the ability to pass into enterocytes in the manner of orally absorbed nutrient lipids using cell pathways to reach the golgi apparatus. Pursuant to the present invention, the novel cargo loaded cholestosomes according to the present invention are capable of depositing active molecules within cells of a patient or subject and effecting therapy or diagnosis of the patient or subject.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor:(Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.

Cholesteryl ester transfer protein inhibitors for use in the treatment or prevention of cardiovascular disease and pharmaceutical compositions containing the same. The present invention relates to cholesteryl ester transfer protein (CETP) inhibitors for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The invention relates to the technical field of vitamin intermediates, and particularly discloses a preparation process of a vitamin D3 key intermediate 7-p-toluenesulfonyl epide-3-cholesteryl ester. The invention relates to a preparation process of a vitamin D3 key intermediate 7-p-toluenesulfonylepide-3-cholesteryl ester, which comprises the following steps: reaction: adding 7-keto-3-cholesteryl ester, p-toluenesulfonhydrazide and concentrated hydrochloric acid into methanol, heating to 45-50 DEG C, and carrying out heat preservation reaction for 6.5-7.5 hours; post-treatment: after the reaction is finished, cooling crystallization and suction filtration are performed to obtain a solid, the solid is eluted by using iced methanol, suction drying is performed to obtain a washing solution and a filter cake, and the filter cake is subjected to vacuum drying to constant weight to obtain the product 7-p-toluenesulfonylepide-3-cholesteryl ester. The concentrated hydrochloric acid is used as a catalyst, and the reaction is carried out at 45-50 DEG C for 6.5-7.5 h, so that the reaction is mild, the energy consumption is reduced, and the production efficiency of the 7-p-toluenesulfonylepide-3-cholesteryl ester is improved.

The present application belongs to the technical field of medicine, and mainly relates to a conjugate of an ApoA1 short peptide and a tubulin inhibitor and a self-assembled nano preparation thereof, wherein the ApoA1 short peptide and the tubulin inhibitor are coupled through a linker. The self-assembled nano preparation comprises the following components: 1-100 parts of the conjugate of the ApoA1 short peptide and the tubulin inhibitor; 1-100 parts of phospholipid; 1-100 parts of cholesteryl ester; and 1-100 parts of water for injection or phosphate buffer. The conjugate of the ApoA1 short peptide and the tubulin inhibitor improves the targeting of the tubulin inhibitor on tumor cells and reduces the toxic side effects of the tubulin inhibitor; the self-assembled nano preparation has the advantages of low cost, few operation steps, simple process, good repeatability, can realize efficient mass production at low cost, and is conducive to storage and drug administration.

The present invention relates to a method for determining the presence of Mycobacterium bovis in a subject. The method comprises: (i) determining the level of one or more biomarkers in a sample from the subject; and (ii) comparing the level of said one or more biomarkers with the level of said one or more metabolites in a control sample to determine whether Mycobacterium bovis is present in the subject. The biomarkers are selected from: dihydro-leukotriene B4, 3-hydroxyisovaleric acid, sphingomyelin [SM(d18:2(4E,14Z) / 24:0)], sphingomyelin [SM(d18:1 / 24:1(15Z))], 18:3 cholesteryl ester, an unknown compound 389.21933 m / z (under negative ionisation), an unknown compound 886.71063 m / z (under negative ionisation), citric acid, MG(0:0 / 18:3(6Z,9Z,12Z) / 0:0), pyrocatechol, N-(docosanoyl)-heptadecasphing-4-enine-1-phosphocholine and an unknown compound 359.22107 m / z (under negative ionisation).

The present invention relates to a method for determining the content of omega-3 polyunsaturated fatty acids in the retina of a subject comprising the determination of the content of at least one cholesteryl ester in a blood sample from said subject, the content of omega-3 polyunsaturated fatty acids in the retina being correlated to the content of said at least one cholesteryl ester, said at least one cholesteryl ester being cholesteryl 5,8,11,14,17-eicosapentaenoate.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for use in the treatment of an individual suffering from or at increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The invention discloses bionic skin lipid and a preparation method thereof. The compound vegetable oil composed of the deep sea fish oil, the camellia seed oil and the prinsepia utilis royle oil is selected, and is rich in triacylglycerol, phytosphingosine, squalene, cholesteryl ester, cholesterol, wax ester, phospholipid and other lipids required by skin; candida lipolytica is adopted to ferment the compound vegetable oil, the bionic skin lipid is obtained after fermentation, the content of effective components and the use feeling are obviously improved, and the bionic skin lipid can be used as an active component to be added into a cosmetic matrix. The multi-dimensional effects of maintaining a skin barrier function, preserving moisture, resisting inflammation, regulating micro-ecology and the like are achieved.

An integrated wound dressing device for treatment of an insertion site of percutaneous and drug delivery devices has a transparent film layer with a bottom side, a top side and a perimeter. The bottom side is coated with an adhesive impregnated with an antimicrobial agent. The transparent film has a radius cutout between a central opening and the perimeter. A liquid crystal temperature sensitive film with an adhesive placed on the top side of the transparent film layer is preferably near and around the central opening. The dressing also has a layer of double folded release paper below the bottom side of the transparent film layer. The preferred TLCs used are cholesteryl esters with a preferable temperature detection range of 35-40° C. The preferred antimicrobial agent is chlorohexidine gluconate (CHG).

According to the present invention, it is possible to provide a drug carrier having excellent bioavailability and improved drug encapsulation efficiency by preparing lipoprotein-mimicking solid lipid nanoparticles having a core-shell structure consisting of albumin-conjugated cholesterol, a fusogenic lipid, a cationic lipid, a triglyceride and a cholesteryl ester.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor for use in the treatment of a subject suffering from or at an increased risk of cardiovascular disease, in particular hyperlipidemia or mixed dyslipidemia. Another aspect of the invention relates to a pharmaceutical composition for treating a subject suffering from or having an increased risk of cardiovascular disease, wherein the composition comprises a therapeutically effective amount of the CETP inhibitor.

The present invention relates to a cholesteryl ester transfer protein (CETP) inhibitor:(Compound A) for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, in particular hyperlipidemia or mixed dyslipidemia. A further aspect of the present invention relates to a pharmaceutical composition for use in the treatment of subjects suffering from or having an increased risk for cardiovascular diseases, wherein the composition comprises a therapeutically effective amount of said Compound A CETP inhibitor.